Amitriptylinoxide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Amitriptylinoxide
Accession Number
DB13114
Description

Amitriptylinoxide has been used in trials studying Major Depression.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 293.41
Monoisotopic: 293.177964365
Chemical Formula
C20H23NO
Synonyms
Not Available
External IDs
  • J9.621K

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseAmitriptylinoxide may decrease the hypoglycemic activities of Acarbose.
AcebutololAmitriptylinoxide may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Amitriptylinoxide.
AcemetacinThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Acemetacin.
AcenocoumarolThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Amitriptylinoxide.
AcetohexamideAmitriptylinoxide may decrease the hypoglycemic activities of Acetohexamide.
AcetophenazineThe serum concentration of Amitriptylinoxide can be increased when it is combined with Acetophenazine.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Amitriptylinoxide.
AclidiniumAmitriptylinoxide may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Trialkyl amine oxides / Trisubstituted amine oxides and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic homopolycyclic compound / Dibenzocycloheptene / Hydrocarbon derivative / N-oxide / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organopnictogen compound / Trialkyl amine oxide
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
TYR2U59WMA
CAS number
4317-14-0
InChI Key
ZPMKQFOGINQDAM-UHFFFAOYSA-N
InChI
InChI=1S/C20H23NO/c1-21(2,22)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
IUPAC Name
N,N-dimethyl-3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propanamine oxide
SMILES
CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12

References

General References
Not Available
PubChem Compound
20313
PubChem Substance
347829237
ChemSpider
19137
BindingDB
112778
ChEBI
135224
ChEMBL
CHEMBL627
ZINC
ZINC000001481969
Wikipedia
Amitriptylinoxide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet120 MG
Tablet30 MG
Tablet60 MG
Tablet90 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000277 mg/mLALOGPS
logP1.79ALOGPS
logP3.69ChemAxon
logS-6ALOGPS
pKa (Strongest Basic)4.04ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.55 m3·mol-1ChemAxon
Polarizability33.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on October 20, 2016 21:19 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates